These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15126959)

  • 1. Home care versus hospital care in patients with multiple myeloma treated with pamidronate.
    Smith AG; Soutar RL; Schey S; Andrews CD; Baister ER; Bilbrough C; Connelly M; Joyce A; Child JA
    Int J Palliat Nurs; 2004 Mar; 10(3):144-9. PubMed ID: 15126959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
    Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
    Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' experience of ambulatory self-administration of pamidronate in multiple myeloma.
    Johansson E; Langius-Eklöf A; Engervall P; Wredling R
    Cancer Nurs; 2005; 28(2):158-65. PubMed ID: 15815186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
    Dranitsaris G
    Int J Technol Assess Health Care; 1999; 15(1):108-22. PubMed ID: 10407599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
    Lassalle A; Thomaré P; Fronteau C; Mahé B; Jubé C; Blin N; Voldoire M; Dubruille V; Tessoulin B; Touzeau C; Chauvin C; Loirat M; Lok A; Bourcier J; Lestang E; Mocquet R; Barbarot V; Moreau P
    Ann Oncol; 2016 Feb; 27(2):314-8. PubMed ID: 26578729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate infusions: patient preference, safety and clinic use.
    Chern B; Joseph D; Joshua D; Pittman K; Richardson G; Schou M; Lowe S; Copeman M; De Abreu Lourenco R; Lynch K
    Support Care Cancer; 2004 Jun; 12(6):463-6. PubMed ID: 15088136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The home infusion formula: high tech + high touch = high-quality home care.
    Weaver J; Simmons G; Schofield RL
    Caring; 1995 May; 14(5):52-4, 56. PubMed ID: 10142355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
    Guest JF; Clegg JP; Davie AM; McCloskey E
    Curr Med Res Opin; 2005 May; 21(5):805-15. PubMed ID: 15969880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
    Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
    Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate.
    Gessner U; Koeberle D; Thuerlimann B; Bacchus L; Horisberger B
    Support Care Cancer; 2000 Mar; 8(2):115-22. PubMed ID: 10739358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life of cancer patients receiving home infusion services. A pilot study.
    Hanchett M
    J Infus Nurs; 2001; 24(4):244-8. PubMed ID: 11507787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotic syndrome after treatment with pamidronate.
    Markowitz GS; Fine PL; D'agati VD
    Am J Kidney Dis; 2002 May; 39(5):1118-22. PubMed ID: 11979358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.